PMC:7321036 / 4429-4687 JSONTXT

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T119","span":{"begin":68,"end":78},"obj":"DG_28"},{"id":"T120","span":{"begin":109,"end":117},"obj":"SP_7"},{"id":"T121","span":{"begin":172,"end":182},"obj":"SP_7"},{"id":"T122","span":{"begin":195,"end":201},"obj":"CHEBI:52217;CHEBI:52217"}],"text":"ration (FDA) (Grein et al., 2020). Although the evidence supporting remdesivir use in patients with advanced COVID-19 is promising, there remains an urgent need for potent SARS-CoV-2 therapeutic agents, especially those that could be given in an outpatient s"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T43","span":{"begin":109,"end":117},"obj":"Disease"},{"id":"T44","span":{"begin":172,"end":180},"obj":"Disease"}],"attributes":[{"id":"A43","pred":"mondo_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A44","pred":"mondo_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"ration (FDA) (Grein et al., 2020). Although the evidence supporting remdesivir use in patients with advanced COVID-19 is promising, there remains an urgent need for potent SARS-CoV-2 therapeutic agents, especially those that could be given in an outpatient s"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T19","span":{"begin":68,"end":78},"obj":"Chemical"}],"attributes":[{"id":"A19","pred":"chebi_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"}],"text":"ration (FDA) (Grein et al., 2020). Although the evidence supporting remdesivir use in patients with advanced COVID-19 is promising, there remains an urgent need for potent SARS-CoV-2 therapeutic agents, especially those that could be given in an outpatient s"}

{"project":"LitCovid-PubTator","denotations":[{"id":"116","span":{"begin":86,"end":94},"obj":"Species"},{"id":"117","span":{"begin":172,"end":182},"obj":"Species"},{"id":"118","span":{"begin":246,"end":256},"obj":"Species"},{"id":"120","span":{"begin":68,"end":78},"obj":"Chemical"},{"id":"126","span":{"begin":109,"end":117},"obj":"Disease"}],"attributes":[{"id":"A116","pred":"tao:has_database_id","subj":"116","obj":"Tax:9606"},{"id":"A117","pred":"tao:has_database_id","subj":"117","obj":"Tax:2697049"},{"id":"A118","pred":"tao:has_database_id","subj":"118","obj":"Tax:9606"},{"id":"A120","pred":"tao:has_database_id","subj":"120","obj":"MESH:C000606551"},{"id":"A126","pred":"tao:has_database_id","subj":"126","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ration (FDA) (Grein et al., 2020). Although the evidence supporting remdesivir use in patients with advanced COVID-19 is promising, there remains an urgent need for potent SARS-CoV-2 therapeutic agents, especially those that could be given in an outpatient s"}

{"project":"2_test","denotations":[{"id":"32645325-32275812-20773039","span":{"begin":28,"end":32},"obj":"32275812"}],"text":"ration (FDA) (Grein et al., 2020). Although the evidence supporting remdesivir use in patients with advanced COVID-19 is promising, there remains an urgent need for potent SARS-CoV-2 therapeutic agents, especially those that could be given in an outpatient s"}